Xanthus To Develop Lung Cancer Therapy Following Deal With Schering AG
This article was originally published in The Pink Sheet Daily
Executive Summary
Xanthus licenses the peptide PD045, which management originally developed at Diatide prior to acquisition by Schering AG.